Schweitzer, A, et al.
Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet
2015; 386: 1546–1555.
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet
2015; 385: 117–171.
Locarnini, S, et al.
Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. Journal of Hepatology
2015; 62: S76–86.
Meffre, C, et al.
Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. Journal of Medical Virology
2010; 82: 546–555.
Denis, F, Levy-Bruhl, D. Mass vaccination against hepatitis B: the French example. Current Topics of Microbiology and Immunology
2006; 304: 115–129.
Mathers, BM, et al.
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet
2008; 372: 1733–1745.
Weill-Barillet, L, et al.
Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. Revue d'Epidemiologie et de SantéPublique
2016; 64: 301–312.
Jauffret-Roustide, M, et al.
A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infectious Diseases
2009; 9: 113.
Mohamed, S, et al.
Dried blood spot sampling for hepatitis B virus serology and molecular testing. PLoS ONE
2013; 8: e61077.
Njai, HF, et al.
Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. Journal of Clinical Microbiology
2015; 53: 1156–1163.
Chan, HL, et al.
Hepatitis B surface antigen quantification: why and how to use it in 2011 – a core group report. Journal of Hepatology
2011; 55: 1121–1131.
Lugoboni, F, et al.
Let It ‘B’? The role of hepatitis B universal vaccination among italian problematic drug users. International Journal of Environmental Research and Public Health
2015; 12: 3979–3992.
Bialek, SR, et al.
Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users. Journal of Urban Health
2005; 82: 468–478.
Des Jarlais, DC, Braine, N, Friedmann, P. Unstable housing as a factor for increased injection risk behavior at US syringe exchange programs. AIDS and Behavior
2007; 11: 78–84.
Brouard, C, et al.
Hepatitis B knowledge, perceptions and practices in the French general population: the room for improvement. BMC Public Health
2013; 13: 576.
Di, Nino F, et al.
Evolution of hepatitis B vaccination coverage among psychoactive substances users followed by the Network of Medical Microstructures in Alsace (France), 2009–2012. Bulletin Epidemiologique Hebdomadaire
2014; 11: 192–200.
Day, CA, et al.
Hepatitis B virus among injecting drug users in Sydney, Australia: prevalence, vaccination and knowledge of status. Drug and Alcohol Dependence
2010; 108: 134–137.
Kamath, GR, Shah, DP, Hwang, LY. Immune response to hepatitis B vaccination in drug using populations: a systematic review and meta-regression analysis. Vaccine
2014; 32: 2265–2274.
Topp, L, et al.
Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: a review. Drug and Alcohol Revue
2009; 28: 669–675.
Quaglio, G, et al.
Hepatitis vaccination among drug users. Vaccine
2006; 24: 2702–2709.
Judd, A, et al.
Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales?
Journal of Viral Hepatitis
2007; 14: 584–591.
Mossner, BK, et al.
Decline in hepatitis B infection observed after 11 years of regional vaccination among Danish drug users. Journal of Medical Virology
2010; 82: 1635–1639.
Guthmann, JP, et al.
Hepatitis B vaccination coverage among children in France in 2014: substantial progress in infants, stagnation in adolescents. Bulletin Epidemiologique Hebdomadaire
2015; 26–27: 499–504.
Bowman, S, et al.
Factors associated with hepatitis B vaccine series completion in a randomized trial for injection drug users reached through syringe exchange programs in three US cities. BMC Public Health
2014; 14: 820.
Shah, DP, et al.
Long-term effectiveness of accelerated hepatitis B vaccination schedule in drug users. American Journal of Public Health
2015; 105: e36–43.
Weaver, T, et al.
Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. Lancet
2014; 384: 153–163.
Topp, L, et al.
A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Preventive Medicine
2013; 57: 297–303.